Cardiol Therapeutics (CRDL) Equity Ratio (2020 - 2026)

Cardiol Therapeutics has reported Equity Ratio for 7 years, with the latest figure at 0.77 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 11.54% year-over-year to 0.77; the trailing twelve-month figure through Mar 2026 stood at 0.77 (up 11.54% YoY), and the FY2025 full-year result was 0.76, down 2.47% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.77, up from 0.76 in the prior quarter.
• The five-year high for Equity Ratio was 0.87 in Q1 2022, with the low at 0.58 in Q2 2024.
• Historically, Equity Ratio has averaged 0.75 across 5 years, with a median of 0.77 in 2026.
• Annual changes were most pronounced in 2024 — Equity Ratio slipped 28.94% — and 2025, when it climbed 24.02%.
• Cardiol Therapeutics' Equity Ratio stood at 0.84 in 2022, then decreased by 8.55% to 0.77 in 2023, then grew by 0.83% to 0.78 in 2024, then dropped by 2.47% to 0.76 in 2025, then climbed by 1.82% to 0.77 in 2026.
• The last three Equity Ratio figures came in at 0.77 (Q1 2026), 0.76 (Q4 2025), and 0.74 (Q3 2025), per Business Quant data.